Translational Pain Research: Achievements and Challenges

Journal of Pain

Volumn 10, Issue 10, 2009, Pages 1001-1011

  Mao, Jianren ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

animal study; clinical trial; pain; preclinical; Translational research

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; AMANTADINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; BUPRENORPHINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DIZOCILPINE; FENTANYL; GABAPENTIN; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; OMEGA CONOTOXIN MVIIA; OPIATE; OPIATE AGONIST; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

BRAIN DEPTH STIMULATION; CANCER PAIN; CARDIOVASCULAR SYMPTOM; CHRONIC PAIN; CLINICAL RESEARCH; COMORBIDITY; COMPLEX REGIONAL PAIN SYNDROME; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC DIFFERENCE; HUMAN; HYPERALGESIA; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PHENOTYPE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; REVIEW; SELF REPORT; SENSORY SYSTEM EXAMINATION; SEX DIFFERENCE;

ANALGESICS; ANIMALS; BIOMEDICAL RESEARCH; DRUG DESIGN; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEUROPHARMACOLOGY; NEUROSCIENCES; PAIN; PAIN MEASUREMENT; TRANSLATIONAL RESEARCH;

EID: 70349583499     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2009.06.002     Document Type: Review

References (146)

1. Ahmad S., and Dray A. Novel G protein-coupled receptors as pain targets. Curr Opin Investig Drugs 5 (2004) 67-70
2. Altier C., and Zamponi G.W. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25 (2004) 465-470
3. Apkarian A.V., Sosa Y., Sonty S., Levy R.M., Harden R.N., Parrish T.B., and Gitelman D.R. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 24 (2004) 10410-10415
4. Ashton J.C., and Milligan E.D. Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Curr Opin Investig Drugs 9 (2008) 65-75
5. Basbaum A.I. Spinal mechanisms of acute and persistent pain. Reg Anesth Pain Med 24 (1999) 59-67
6. Basbaum A.I., and Fields H.L. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7 (1984) 309-338
7. Becerra L., Breiter H.C., Wise R., Gonzalez R.G., and Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron 32 (2001) 927-946
8. Beltramo M. Cannabinoid type 2 receptor as a target for chronic-pain. Mini Rev Med Chem 9 (2009) 11-25
9. Bennett G., Deer T., Du Pen S., Rauck R., Yaksh T., and Hassenbusch S.J. Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manage 20 (2000) S44-S50
10. Bley K.R. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 13 (2004) 1445-1456
11. Borsook D., Moulton E.A., Schmidt K.F., and Becerra L.R. Neuroimaging revolutionizes therapeutic approaches to chronic pain. Mol Pain 3 (2007) 25
12. Bourinet E., and Zamponi G.W. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem 5 (2005) 539-546
13. Burns T.L., and Ineck J.R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 40 (2006) 251-260
14. Burnstock G. Purinergic P2 receptors as targets for novel analgesics. Pharmacol Ther 110 (2006) 433-454
15. Campbell C.M., France C.R., Robinson M.E., Logan H.L., Geffken G.R., and Fillingim R.B. Ethnic differences in diffuse noxious inhibitory controls. J Pain 9 (2008) 759-766
16. Campbell J.N. Nerve lesions and the generation of pain. Muscle Nerve 24 (2001) 1261-1273
17. Carlton S.M., Zhou S., and Coggeshall R.E. Evidence for the interaction of glutamate and NK1 receptors in the periphery. Brain Res 790 (1998) 160-169
18. Casey K.L. Toward a neurophysiology of pain. Headache 8 (1969) 141-153
19. Caterina M.J., and Julius D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci 24 (2001) 487-517
20. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
21. Chaplan S.R., Malmberg A.B., and Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 280 (1997) 829-838
22. Chizh B.A., Greenspan J.D., Casey K.L., Nemenov M.I., and Treede R.D. Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development. Pain 140 (2008) 249-253
23. Chizh B.A., and Illes P. P2X receptors and nociception. Pharmacol Rev 53 (2001) 553-568
24. Christensen B.N., and Perl E.R. Spinal neurons specifically excited by noxious or thermal stimuli: Marginal zone of the dorsal horn. J Neurophysiol 33 (1970) 293-307
25. Coghill R.C., McHaffie J.G., and Yen Y.F. Neural correlates of interindividual differences in the subjective experience of pain. Proc Natl Acad Sci U S A 100 (2003) 8538-8542
26. Collis R., Brandner B., Bromley L.M., and Woolf C.J. Is there any clinical advantage of increasing the pre-emptive dose of morphine or combining pre-incisional with postoperative morphine administration?. Br J Anaesth 74 (1995) 396-399
27. Coluzzi P.H. Sublingual morphine: Efficacy reviewed. J Pain Symptom Manage 16 (1998) 184-192
28. Davies P.S., and Galer B.S. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 64 (2004) 937-947
29. Desmeules J.A. The tramadol option. Eur J Pain 4 Suppl A (2000) 15-21
30. Devor M. Neuropathic pain and injured nerve: Peripheral mechanisms. Br Med Bull 47 (1991) 619-630
31. Diatchenko L., Nackley A.G., Tchivileva I.E., Shabalina S.A., and Maixner W. Genetic architecture of human pain perception. Trends Genet 23 (2007) 605-613
32. Dickenson A.H. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 11 (1990) 307-309
33. Dray A. Inflammatory mediators of pain. Br J Anaesth 75 (1995) 125-131
34. Dray A., and Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 16 (1993) 99-104
35. Dubner R: Neural plasticity and pain following peripheral tissue inflammation or nerve injury. Proceedings of the Vth World Congress on Pain, Pain Research and Clinical Management, Amsterdam, Elsevier, 1991.
36. Dubner R. Hargreaves KM: The neurobiology of pain and its modulation. Clin J Pain 5 Suppl 2 (1989) S1-S4 discussion S4-6
37. Dubner R., and Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 15 (1992) 96-103
38. Dyck P.J., Thomas P.K., Lambert E.H., and Bunge R. Peripheral Neuropathy. 1st Edition (1984), Saunders, Philadelphia PA
39. Edwards R.R., and Fillingim R.B. Self-reported pain sensitivity: Lack of correlation with pain threshold and tolerance. Eur J Pain 11 (2007) 594-598
40. Eide P.K., Stubhaug A., and Stenehjem A.E. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 37 (1995) 1080-1087
41. Enarson M.C., Hays H., and Woodroffe M.A. Clinical experience with oral ketamine. J Pain Symptom Manage 17 (1999) 384-386
42. England S. Voltage-gated sodium channels: The search for subtype-selective analgesics. Expert Opin Investig Drugs 17 (2008) 1849-1864
43. Fields H.L. Pain (1987), McGraw-Hill, New York p 354
44. Flores C.M., and Mogil J.S. The pharmacogenetics of analgesia: Toward a genetically-based approach to pain management. Pharmacogenomics 2 (2001) 177-194
45. Gilron I., and Coderre T.J. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 12 (2007) 113-126
46. Gladstone J.P., and Gawel M. Newer formulations of the triptans: Advances in migraine management. Drugs 63 (2003) 2285-2305
47. Gosselin R.D., Dansereau M.A., Pohl M., Kitabgi P., Beaudet N., and Sarret P. Melik Parsadaniantz S: Chemokine network in the nervous system: A new target for pain relief. Curr Med Chem 15 (2008) 2866-2875
48. Gottschalk A., Schroeder F., Ufer M., Oncu A., Buerkle H., and Standl T. Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg 93 (2001) 192-196
49. Gracely R.H., Lynch S.A., and Bennett G.J. Painful neuropathy: Altered central processing maintained dynamically by peripheral input. Pain 51 (1992) 175-194
50. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 49 (1995) 33-35
51. Greenspan J.D., Craft R.M., LeResche L., Arendt-Nielsen L., Berkley K.J., Fillingim R.B., Gold M.S., Holdcroft A., Lautenbacher S., Mayer E.A., Mogil J.S., Murphy A.Z., and Traub R.J. Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP: Studying sex and gender differences in pain and analgesia: A consensus report. Pain 132 Suppl 1 (2007) S26-S45
52. Gribkoff V.K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7 (2003) 737-748
53. Guindon J., and Hohmann A.G. Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153 (2008) 319-334
54. Guo W., Zou S., Guan Y., Ikeda T., Tal M., Dubner R., and Ren K. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci 22 (2002) 6208-6217
55. Hardy J.D. The Nature of Pain. J Chronic Dis 4 (1956) 22-51
56. Hardy J.D., Wolff H.G., and Goodell H. Pain Sensations and Reactions. 1st Edition (1952), Williams & Wilkins, Baltimore MD
57. Hefti F.F., Rosenthal A., Walicke P.A., Wyatt S., Vergara G., Shelton D.L., and Davies A.M. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 27 (2006) 85-91
58. Helmy S.A., and Bali A. The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. Anesth Analg 92 (2001) 739-744
59. Holzer P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br J Pharmacol 155 (2008) 1145-1162
60. Jain K.K. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs 5 (2004) 76-81
61. James M.J., and Cleland L.G. Cyclooxygenase-2 inhibitors: What went wrong?. Curr Opin Clin Nutr Metab Care 9 (2006) 89-94
62. Julius D., and Basbaum A.I. Molecular mechanisms of nociception. Nature 413 (2001) 203-210
63. Kaplan K.M., and Brose W.G. Intrathecal methods. Neurosurg Clin N Am 15 (2004) 289-296
64. Klepstad P., and Borchgrevink P.C. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 41 (1997) 422-426
65. Lever I.J., and Rice A.S. Cannabinoids and pain. Handb Exp Pharmacol 177 (2007) 265-306
66. Levine J.D., Moskowitz M.A., and Basbaum A.I. The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135 Suppl 2 (1985) 843S-847S
67. Longmore J., Hill R.G., and Hargreaves R.J. Neurokinin-receptor antagonists: Pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol 75 (1997) 612-621
68. Malanga G., Reiter R.D., and Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother 9 (2008) 2209-2215
69. Mao J. Translational pain research: Bridging the gap between basic and clinical research. Pain 97 (2002) 183-187
70. Mao J. NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev 30 (1999) 289-304
71. Mao J., and Chen L.L. Systemic lidocaine for neuropathic pain relief. Pain 87 (2000) 7-17
72. Mao J., and Chen L.L. Gabapentin in pain management. Anesth Analg 91 (2000) 680-687
73. Mao J., Price D.D., Hayes R.L., Lu J., and Mayer D.J. Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res 598 (1992) 271-278
74. Mao J., Price D.D., and Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 62 (1995) 259-274
75. Mao J., Price D.D., Mayer D.J., Lu J., and Hayes R.L. Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res 576 (1992) 254-262
76. McConaghy P.M., McSorley P., McCaughey W., and Campbell W.I. Dextromethorphan and pain after total abdominal hysterectomy. Br J Anaesth 81 (1998) 731-736
77. McMahon S.B. Mechanisms of sympathetic pain. Br Med Bull 47 (1991) 584-600
78. McMahon S.B., and Koltzenburg M. Novel classes of nociceptors: beyond Sherrington. Trends Neurosci 13 (1990) 199-201
79. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1 (1975) 277-299
80. Melzack R., and Wall P.D. Pain mechanisms: A new theory. Science 150 (1965) 971-979
81. Mendell L.M., and Wall P.D. Responses of Single Dorsal Cord Cells to Peripheral Cutaneous Unmyelinated Fibres. Nature 206 (1965) 97-99
82. Mercadante S., Lodi F., Sapio M., Calligara M., and Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 10 (1995) 564-568
83. Miljanich G.P. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11 (2004) 3029-3040
84. Muller J. Elements of Physiology. 1st Edition (1942), Taylor and Walton, London UK
85. Neubert J.K., Widmer C.G., Malphurs W., Rossi H.L., Vierck Jr. C.J., and Caudle R.M. Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Pain 116 (2005) 386-395
86. Nielsen C.S., Staud R., and Price D.D. Individual differences in pain sensitivity: measurement, causation, and consequences. J Pain 10 (2009) 231-237
87. Noodenbos W. Pain. 1st Edition (1959), Elsevier, Amsterdam
88. Ocana M., Cendan C.M., Cobos E.J., Entrena J.M., and Baeyens J.M. Potassium channels and pain: Present realities and future opportunities. Eur J Pharmacol 500 (2004) 203-219
89. Padilla M., Clark G.T., and Merrill R.L. Topical medications for orofacial neuropathic pain: A review. J Am Dent Assoc 131 (2000) 184-195
90. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429 (2001) 71-78
91. Patapoutian A., Tate S., and Woolf C.J. Transient receptor potential channels: Targeting pain at the source. Nat Rev Drug Discov 8 (2009) 55-68
92. Perl E.R. Causalgia, pathological pain, and adrenergic receptors. Proc Natl Acad Sci U S A 96 (1999) 7664-7667
93. Perl E.R. Cutaneous polymodal receptors: characteristics and plasticity. Prog Brain Res 113 (1996) 21-37
94. Perl E.R. Somatic sensation: Transfer and processing of information. 1. Peripheral receptors. Electroencephalogr Clin Neurophysiol 27 (1969) 650-651
95. Porreca F., Lai J., Bian D., Wegert S., Ossipov M.H., Eglen R.M., Kassotakis L., Novakovic S., Rabert D.K., Sangameswaran L., and Hunter J.C. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci U S A 96 (1999) 7640-7644
96. Price D.D. Psychological and neural mechanisms of the affective dimension of pain. Science 288 (2000) 1769-1772
97. Price D.D. Psychological and Neural Mechanisms of Pain. 1st Edition (1988), Raven, New York NY
98. Price D.D., Hayes R.L., Ruda M., and Dubner R. Neural representation of cutaneous aftersensations by spinothalamic tract neurons. Fed Proc 37 (1978) 2237-2239
99. Price D.D., Long S., and Huitt C. Sensory testing of pathophysiological mechanisms of pain in patients with reflex sympathetic dystrophy. Pain 49 (1992) 163-173
100. Price D.D., Mao J., Frenk H., and Mayer D.J. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 59 (1994) 165-174
101. Pud D., Eisenberg E., Spitzer A., Adler R., Fried G., and Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain 75 (1998) 349-354
102. Raij T.T., Forss N., Stancak A., and Hari R. Modulation of motor-cortex oscillatory activity by painful Adelta- and C-fiber stimuli. Neuroimage 23 (2004) 569-573
103. Raja S.N., and Grabow T.S. Complex regional pain syndrome I (reflex sympathetic dystrophy). Anesthesiology 96 (2002) 1254-1260
104. Raja S.N., Meyer R.A., and Campbell J.N. Peripheral mechanisms of somatic pain. Anesthesiology 68 (1988) 571-590
105. Ren K., Hylden J.L., Williams G.M., Ruda M.A., and Dubner R. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 50 (1992) 331-344
106. Roberts L.A., and Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Pat CNS Drug Discov 1 (2006) 65-76
107. Romero-Sandoval E.A., Horvath R.J., and DeLeo J.A. Neuroimmune interactions and pain: Focus on glial-modulating targets. Curr Opin Investig Drugs 9 (2008) 726-734
108. Saarto T., and Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 4 (2007) CD005454
109. Sawynok J. Topical analgesics in neuropathic pain. Curr Pharm Des 11 (2005) 2995-3004
110. Silos-Santiago I. The role of tetrodotoxin-resistant sodium channels in pain states: Are they the next target for analgesic drugs?. Curr Opin Investig Drugs 9 (2008) 83-89
111. Simpson Jr. R.K. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am 14 (2003) 353-364
112. Sinatra R. The fentanyl HCl patient-controlled transdermal system (PCTS): An alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin Pharmacokinet 44 Suppl 1 (2005) 1-6
113. Sindrup S.H., and Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
114. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 5 (2005) 315-323
115. Sollevi A. Adenosine for pain control. Acta Anaesthesiol Scand Suppl 110 (1997) 135-136
116. Sorkin L.S. Nociceptive transmission within the spinal cord. Mt Sinai J Med 58 (1991) 208-216
117. Sorkin L.S., Westlund K.N., Sluka K.A., Dougherty P.M., and Willis W.D. Neural changes in acute arthritis in monkeys. IV. Time-course of amino acid release into the lumbar dorsal horn. Brain Res Brain Res Rev 17 (1992) 39-50
118. Storm H. Changes in skin conductance as a tool to monitor nociceptive stimulation and pain. Curr Opin Anaesthesiol 21 (2008) 796-804
119. Sung B., Lim G., and Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 23 (2003) 2899-2910
120. Talbot J.D., Marrett S., Evans A.C., Meyer E., Bushnell M.C., and Duncan G.H. Multiple representations of pain in human cerebral cortex. Science 251 (1991) 1355-1358
121. Thomas L., Bledsoe J.M., Stead M., Sandroni P., Gorman D., and Lee K.H. Motor cortex and deep brain stimulation for the treatment of intractable neuropathic face pain. Curr Neurol Neurosci Rep 9 (2009) 120-126
122. Thompson SWN, Woolf CJ: Primary afferent-evoked prolonged potentials in the spinal cord and their central summation: Role of the NMDA receptor. Proceedings of the Vth World Congress on Pain, Amsterdam, Elsevier, 1991.
123. Toomey M. Gender differences in pain: Does X = Y?. AANA J 76 (2008) 355-359
124. Wadhwa A., Clarke D., Goodchild C.S., and Young D. Large-dose oral dextromethorphan as an adjunct to patient-controlled analgesia with morphine after knee surgery. Anesth Analg 92 (2001) 448-454
125. Waeber C. Emerging drugs in migraine treatment. Expert Opin Emerg Drugs 8 (2003) 437-456
126. Watkins L.R., Hutchinson M.R., Johnston I.N., and Maier S.F. Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci 28 (2005) 661-669
127. Watkins L.R., and Maier S.F. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov 2 (2003) 973-985
128. Watkins L.R., Maier S.F., and Goehler L.E. Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 63 (1995) 289-302
129. Watson J.J., Allen S.J., and Dawbarn D. Targeting nerve growth factor in pain: What is the therapeutic potential?. BioDrugs 22 (2008) 349-359
130. Waxman S.G., Dib-Hajj S., Cummins T.R., and Black J.A. Sodium channels and pain. Proc Natl Acad Sci U S A 96 (1999) 7635-7639
131. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?. Drugs 55 (1998) 1-4
132. Willis Jr. W.D. Central nervous system mechanisms for pain modulation. Appl Neurophysiol 48 (1985) 153-165
133. Wood J.N., and Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem 5 (2005) 529-537
134. Wood J.N., and Perl E.R. Pain. Curr Opin Genet Dev 9 (1999) 328-332
135. Woolf C.J. Evidence for a central component of post-injury pain hypersensitivity. Nature 306 (1983) 686-688
136. Woolf C.J., Bennett G.J., Doherty M., Dubner R., Kidd B., Koltzenburg M., Lipton R., Loeser J.D., Payne R., and Torebjork E. Towards a mechanism-based classification of pain?. Pain 77 (1998) 227-229
137. Woolf C.J., and Chong M.S. Preemptive analgesia-treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 77 (1993) 362-379
138. Woolf C.J., and Salter M.W. Neuronal plasticity: Increasing the gain in pain. Science 288 (2000) 1765-1769
139. Yaksh T.L. Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sci 20 (1999) 329-337
140. Yaksh T.L. New horizons in our understanding of the spinal physiology and pharmacology of pain processing. Semin Oncol 20 2 Suppl 1 (1993) 6-18
141. Yaksh T.L. Spinal pharmacology of pain and its modulation. Clin Neurosurg 31 (1983) 291-303
142. Yamamoto T., and Yaksh T.L. Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat. Anesthesiology 77 (1992) 757-763
143. Yamamoto T., and Yaksh T.L. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 135 (1992) 67-70
144. Yeh C.C., Ho S.T., Kong S.S., Wu C.T., and Wong C.S. Absence of the preemptive analgesic effect of dextromethorphan in total knee replacement under epidural anesthesia. Acta Anaesthesiol Sin 38 (2000) 187-193
145. Zeng Q., Wang S., Lim G., Yang L., Mao J., Sung B., Chang Y., Lim J.A., Guo G., and Mao J. Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res 1200 (2008) 27-38
146. Zimmermann M., and Herdegen T. Plasticity of the nervous system at the systematic, cellular and molecular levels: A mechanism of chronic pain and hyperalgesia. Prog Brain Res 110 (1996) 233-259